Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors
PARIS, France, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), hereafter “Onxeo” or “the Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA …